Baloxavir Marboxil: A Review in Acute Uncomplicated Influenza.

Article Details

Citation

Copy to clipboard

Shirley M

Baloxavir Marboxil: A Review in Acute Uncomplicated Influenza.

Drugs. 2020 Jul;80(11):1109-1118. doi: 10.1007/s40265-020-01350-8.

PubMed ID

32601915 [ View in PubMed

]

Abstract

Baloxavir marboxil (Xofluza((R)); hereafter referred to as baloxavir), the prodrug of baloxavir acid, is a first-in-class, small molecule inhibitor of the polymerase acidic (PA) protein subunit of the influenza virus polymerase complex. Baloxavir (after conversion to baloxavir acid) acts to block influenza virus replication by inhibiting the cap-dependent endonuclease activity of the PA protein. Taken orally as a single dose, baloxavir is approved in the USA for the treatment of acute uncomplicated influenza in patients >/= 12 years of age who have been symptomatic for

DrugBank Data that Cites this Article

Drugs

Baloxavir marboxil

Drug Targets

Drug	Target	Kind	Organism	Pharmacological Action	Actions
Baloxavir marboxil	Polymerase acidic protein	Protein	Influenza A virus (strain A/Puerto Rico/8/1934 H1N1)	Yes	Inhibitor	Details